Gynecologic Oncology

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

The 9th International Symposium on Ovarian Cancer and Other Gynecologic Malignancies conference will bring professionals in the field up to date on the latest research into ovarian, uterine, cervical, and endometrial cancers.

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

Patients with ovarian cancer who express BRCA1/2 mutations demonstrated a better overall survival after 5 years.

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Subfertile women who undergo ovarian stimulation for in vitro fertilization have an increased risk of ovarian malignancies.

A proposed overhaul of the NCI's clinical trials system has created anxiety among gynecologic researchers who fear projects in women's cancer will be diminished in a scramble for funding with more common malignancies.

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

New findings demonstrate a recent increase in the annual completion rates of vaccination against human papillomavirus (HPV) infection.

Dr. Teresa Woodruff from Feinberg School of Medicine, Northwestern University, Discusses Oncofertility Insurance Coverage

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

Temporary ovarian suppression using triptorelin may decrease the rate of early menopause in premenopausal women with early-stage breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

British investigators are reporting that taller women have a higher risk of cancer, and that the link between height and cancer risk exists for most types of cancer.

Now more than ever, oncology nurses need to be able to fill the knowledge gap and accurately educate their patients and the public about cancer screening tests and their frequency.

Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.

A novel topoisomerase-I inhibitor designated NKTR-102 demonstrated clinically significant activity as a single agent in patients with heavily pretreated ovarian cancer who failed prior PLD.

It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases